Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-30T15:05:35.216Z Has data issue: false hasContentIssue false
  • English
  • Français

Lack of Prognostic Significance of SPECT Abnormalities in Non-demented Elderly Subjects with Memory Loss

Published online by Cambridge University Press:  05 August 2019

R. McKelvey ,
H. Bergman ,
J. Stern ,
C. Rush ,
G. Zahirney  and
H. Chertkow
R. McKelvey
Affiliation:
Bloomfield Centre for Aging, Sir Mortimer B. Davis - Jewish General Hospital, McGill University, Montreal Division of Geriatric Medicine, Department of Medicine, Sir Mortimer B. Davis – Jewish General Hospital, McGill University Dalhousie University, Halifax, N.S., Dr. Everett Chalmers Hospital, Fredericton, N.B.
H. Bergman
Affiliation:
Division of Geriatric Medicine, Department of Medicine, Sir Mortimer B. Davis – Jewish General Hospital, McGill University
J. Stern
Affiliation:
Department of Nuclear Medicine, Sir Mortimer B. Davis - Jewish General Hospital, McGill University
C. Rush
Affiliation:
Department of Nuclear Medicine, Sir Mortimer B. Davis - Jewish General Hospital, McGill University
G. Zahirney
Affiliation:
Bloomfield Centre for Aging, Sir Mortimer B. Davis - Jewish General Hospital, McGill University, Montreal
H. Chertkow*
Affiliation:
Bloomfield Centre for Aging, Sir Mortimer B. Davis - Jewish General Hospital, McGill University, Montreal Division of Geriatric Medicine, Department of Medicine, Sir Mortimer B. Davis – Jewish General Hospital, McGill University Research Centre, Centre Hospitalier Côte-des-Neiges, Montreal
*
Lady Davis Institute and Sir Mortimer B. Davis - Jewish General Hospital, 3755 Chemin de la Cote Ste., Catherine, Montreal, Quebec, Canada H3T 1E2
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

To determine if hypoperfusion abnormalities on single photon emission computed tomography (SPECT) are associated with poorer cognitive function at baseline or increased risk of decline in cognitive function and progression to dementia in memory-impaired but non-demented elderly subjects meeting the criteria for aging associated cognitive decline (AACD).

Design:

Cross sectional study of 36 AACD subjects comparing hexamethyl propylene-amine oxime (HMPAO) SPECT results rated by visual inspection with base line cognitive functioning. Prospective study of these AACD subjects with clinical and neuropsychological follow-up over 35 months.

Setting:

The memory clinic and nuclear medicine unit of a university teaching hospital.

Subjects:

Thirty-six subjects meeting the criteria for AACD recruited from patients seen on a physician referral basis.

Main outcome measures:

1) Baseline cognitive function as measured by the Mini Mental State Examination (MMSE), Boston naming, Logical Memory I subtest of the WAIS-R, and verbal fluency, correlated with SPECT status. 2) Decline in cognitive function as measured by clinical exam and the MMSE, with progression to dementia on follow-up being correlated with SPECT status at baseline.

Results:

18 of the 36 subjects progressed to dementia (probable Alzheimer's Disease) over follow-up. No correlation was found between the presence or absence of SPECT abnormality and MMSE or other cognitive measures. There was no correlation between the presence or absence of SPECT abnormality at initial examination, and cognitive decline according to the MMSE, or with the occurrence of clinical dementia on follow-up.

Conclusions:

We conclude that SPECT abnormalities assessed by visual inspection do not correlate with severity of impairment in AACD individuals, and are not useful in predicting progression to dementia in AACD subjects.

Résumé:

Résumé:<span class='italic'>But:</span>

Notre objectif était de déterminer si des anomalies d'hypoperfusion, à la tomographie à émetteur gamma (SPECT), sont associées à une fonction cognitive altérée à l'évaluation initiale ou à un risque accru de déclin des fonctions cognitives et à une progression vers la démence chez des sujets âgés non déments mais ayant des troubles de mémoire et qui satisfont aux critères de l'échelle du Déclin cognitif associé au vieillissement (DCAV).

<span class='italic'>Plan de l'étude:</span>

Il s'agit d'une étude transversale chez 36 sujets comparant les résultats de HMPAO SPECT, évalués par inspection, avec la fonction cognitive initiale. Nous avons étudié de façon prospective ces sujets avec DCAV au moyen d'un suivi clinique et neuropsychologique de plus de 35 mois.

<span class='italic'>Cadre de l'étude:</span>

Cette étude a été réalisée dans une clinique de la mémoire et une unité de médecine nucléaire d'un hôpital universitaire.

<span class='italic'>Sujets:</span>

Trente-six sujets qui rencontraient les critères de DCAV ont été recrutés parmi les patients référés à la clinique par un médecin.

<span class='italic'>Mesure principale des résultats:</span>

1. La fonction cognitive initiale, telle que mesurée par le “Mini Mental state examination” (MMSE), l'Épreuve de dénomination sous confrontation de Boston, le Sous-test de mémoire logique de l'Échelle clinique de mémoire du Weschler I, l'Épreuve de fluidité verbale, a été corrélée avec les résultats du SPECT. 2. Le déclin de la fonction cognitive mesuré par un examen clinique et le MMSE, avec progression vers la démence au cours du suivi, a été corrélé aux résultats du SPECT initial.

<span class='italic'>Résultats:</span>

18 des 36 sujets ont progressé vers la démence (maladie d'Alzheimer probable) au cours du suivi. Nous n'avons trouvé aucune corrélation entre la présence ou l'absence d'anomalies au SPECT et le MMSE ou les autres mesures cognitives. Il n'y avait pas de corrélation entre la présence ou l'absence d'anomalies au SPECT à l'examen initial et le déclin cognitif selon le MMSE ou le développement d'une démence au cours du suivi clinique.

<span class='italic'>Conclusions:</span>

Nous concluons qu'il n'y a pas de corrélation entre les anomalies au SPECT, qui sont notées par inspection visuelle, et la sévérité de l'atteinte chez les sujets avec DCAV et que ces anomalies ne sont pas utiles pour prédire la progression de la démence chez ces sujets.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 26 , Issue 1 , February 1999 , pp. 23 - 28
Copyright
Copyright © The Canadian Journal of Neurological 1999

References

1. Neary, D, Snowdon, JS, Shields, RA, et al. Single photon emission tomography using 99m Tc-HMPAO in the investigation of dementia. J Neurol Neurosurg and Psychiatry 1987; 50: 1101–1109.Google Scholar
2. Reed, BR, Jagust, WJ, Seab, JP, Ober, BA. Memory and regional cerebral blood flow in mildly symptomatic Alzheimer’s disease. Neurology 1989; 39: 1537–1539.Google Scholar
3. Johnson, KA, Holman, BL, Rosen, TJ, et al. Iofetamene I-123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer’s disease. Arch Int Med 1990; 150: 752–756.Google Scholar
4. Ishii, K, Mori, E, Kitagaki, H, et al. The clinical utility of visual evaluation of scintigraphic perfusion patterns for Alzheimer’s disease using I-123 IMP SPECT. Clin Nuclear Med 1996; 21(2): 106–110.Google Scholar
5. Stoppe, G, Staedt, J, Kogler, A, et al. 99mTc-HMPAO-SPECT in the diagnosis of senile dementia of Alzheimer’s type — a study under clinical routine conditions. J Neural Trans 1995; 99(1–3): 195–211.Google Scholar
6. Read, SL, Miller, BL, Mena, I, et al. SPECT in dementia: clinical and pathological correlation. J Am Geriatr Soc 1995; 43(11): 1243–1247.Google Scholar
7. Villa, G, Cappa, A, Tavolozza, M, et al. Neuropsychological tests and [99mTc] – HM PAO SPECT in the diagnosis of Alzheimer’s dementia. J Neurol 1995; 242(6): 359–366.Google Scholar
8. Waldemar, G. Functional brain imaging with SPECT in normal aging and dementia. Methodological, pathophysiological, and diagnostic aspects. [Review]. Cerebrovasc Brain Metab Rev 1995; 7(2): 89–130.Google Scholar
9. Wolfe, N, Reed, BR, Eberling, JL, Jagust, WJ. Temporal lobe perfusion on single photon emission computed tomography predicts the rate of cognitive decline in Alzheimer’s disease. Arch Neurol 1995; 52: 257–262.Google Scholar
10. Golan, H, Kremer, J, Freedman, M, Ichise, M. Usefulness of follow-up regional cerebral blood flow measurements by single-photon emission computed tomography in the differential diagnosis of dementia. J Neuroimaging 1996; 6(1): 23–28.Google Scholar
11. Bergman, H, Chertkow, H, Wolfson, C, et al. HM-PAO (CERETEC) SPECT brain scanning in the diagnosis of Alzheimer’s disease. J Am Geriatr Soc 1997; 45: 15–20.Google Scholar
12. Claus, JJ, Van Horskamp, F, Breteler, MMB, et al. The diagnostic value of SPECT with Tc99m HMPAO in Alzheimer’s disease: a population based study. Neurology 1994; 44: 454–461.Google Scholar
13. Masterman, D, Mendez, M, Fairbanks, L, Cummings, J. Sensitivity, specificity, and positive predictive value of HM-PAO SPECT in discriminating Alzheimer’s Disease from other dementias. J Geriatr Psych Neurol, 1997; 10, 15–21.Google Scholar
14. Weinstein, HC, Hoan, J, Van Royer, EO, et al. SPECT in the diagnosis of Alzheimer’s disease and multi-infarct dementia. Clin Neurol Neurosurgery 1991; 93: 39–43.Google Scholar
15. Mattman, A, Feldman, H, Forster, B, et al. Regional HmPAO SPECT and CT measurements in the diagnosis of Alzheimer’s Disease. Can J Neurol Sci 1997; 24(1), 22–28.Google Scholar
16. Jagust, WJ. Functional imaging patterns in Alzheimer’s disease. Relationships to neurobiology. [Review]. Ann NY Acad Sci 1996; 777: 30–36.Google Scholar
17. Celsis, P, Agniel, A, Cardebat, D, et al. Age related cognitive decline: a clinical entity? A longitudinal study of cerebral blood flow and memory performance. J Neurol Neurosurg Psychiatry 1997; 62(6): 601–608.Google Scholar
18. Rubin, EH, Morris, JC, Grant, A, Vendegna, T. Very mild senile dementia of the Alzheimer type: I. Clinical assessment. Arch Neurol 1989; 46: 379–382.Google Scholar
19. Tuokko, H, Vernon-Wilkinson, R, Weir, J, Beattie, BL. Cued recall and early identification of dementia. J Clin Exp Neuropsychol 1991; 13(6): 871–879.Google Scholar
20. Levy, R (Chairperson). Aging associated cognitive cecline: working party of the International Psychogeriatric Association in collaboration with the World Health Association. Internat Psychogeriatr 1994; 6(1): 63–68.Google Scholar
21. McKhann, G, Drachman, D, Folstein, M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984; 34: 939–944.Google Scholar
22. Berg, L, Hughes, CP, Coben, LA et al. Mild senile dementia of the Alzheimer type: research diagnostic criteria, recruitment, and a description of a study population. J Neurol Neurosurg Psychiatry 1982; 45: 962–968.Google Scholar
23. O’Brien, JT, Beats, B, Hill, K, et al. Do subjective memory complaints precede dementia? A three-year follow-up of patients with supposed “benign senescent forgetfulness”. Internat J Geriatr Psychiatry 1992; 7: 481–486.Google Scholar
24. Grober, E, Buschke, H, Crystal, H, et al. Screening for dementia by memory testing. Neurology 1988; 38: 900–903.Google Scholar
25. Grober, E, Sliwinsky, M. Development of a model for estimating premorbid verbal intelligence in the elderly. J Clin Exp Neuropsychol 1991; 13(6): 93–949.Google Scholar
26. Morris, JC, McKeel, DW, Storandt, M, et al. Very mild Alzheimer’s disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology 1991; 41: 469–478.Google Scholar
27. Flicker, C, Ferris, SH, Reisberg, B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991; 41: 1006–1009.Google Scholar
28. Weschler, D. Weschler Memory Scale – Revised. New York, NY: Psychological Corporation, 1987.Google Scholar
29. Knopman, D, Ryberg, S. A verbal memory test with high predictive accuracy for dementia of the Alzheimer’s type. Arch Neurol 1989; 46: 141–145.Google Scholar
30. Folstein, M, Folstein, S, McHugh, PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. Psychiatr Res 1975; 12: 189–198.Google Scholar
31. Hachinski, VC, Iliff, LD, Zilhka, E, et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632–637.Google Scholar
32. Mack, WJ, Freed, DM, Williams, BW, Henderson, VW. Boston Naming Test: shortened versions for use in Alzheimer’s disease. J Gerontol Psychol Sci 1992; 47, No.3: 154–158.Google Scholar
33. Thurstone, LL, Thurstone, TG. Primary mental abilities. Psychometric Monographs, No. 1. Chicago, IL: University of Chicago Press, 1938.Google Scholar
34. Weschler, D. Manual for the WAIS-R. New York, NY: Psychological Corporation, 1981.Google Scholar
35. Tuokko, H, Hadjistavropoulos, T. Miller, JA, Beattie, BL. The clock test: a sensitive measure to differentiate normal elderly from those with Alzheimer disease. J Am Geriatr Soc 1992; 40: 579–584.Google Scholar
36. Holman, BL, Johnson, KA, Gerada, B, et al. The scintigraphic appearance of Alzheimer’s disease: a prospective study using technetium 99m-HMPAO SPECT. J Nuclear Med 1992; 33: 181–185.Google Scholar
37. Joachim, CL, Morris, J, Selkoe, DJ. Clinically diagnosed Alzheimer’s disease: autopsy results in 150 cases. Ann Neurol 1988; 24: 50–56.Google Scholar
38. Katzman, R, Lasker, B, Benstin, N. Advances in the diagnosis and consequences of misdiagnosis of disorders causing dementia. In: Terry, RD, ed. Aging and the Brain, vol. 32. New York: Raven Press, 1988; 17–62.Google Scholar
39. Berg, L, Morris, JC. Diagnosis. In: Terry, RD, Katzman, R, Bick, KL, eds. Alzheimer Disease. New York: Raven Press, 1994; 9–25.Google Scholar
40. Chertkow, H, Bub, D. Semantic memory loss in dementia of Alzheimer’s type: What do various measures measure? Brain 1990; 113: 397–417.Google Scholar